Age Alone Should Not Preclude Patients With Lymphoma From Undergoing ASCT

Share this content:
With improving supportive care, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.
With improving supportive care, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.

Age alone should not preclude patients with lymphoma from receiving high-dose chemotherapy and autologous stem cell transplantation (ASCT), according to research published in The Oncologist.1

High-dose chemotherapy and ASCT may cure patients with relapsed Hodgkin or non-Hodgkin lymphoma, though the toxicity profile led to elderly patients (over the age of 60 to 65 years) being excluded from this therapy. With improving supportive care, these patients may now benefit from ASCT.

For this retrospective review, researchers evaluated survival and toxicity data for patients aged at least 70 years who underwent ASCT for lymphoma. Of 119 patients identified, data for 107 were reviewed. The median age at ASCT was 72 years (range, 70-79), 62 patients had diffuse large B cell lymphoma, and 84 had 2 or more chemotherapy regimens prior to ASCT.

The median follow-up was 20 months. Patients had a 100-day non-relapse mortality (NRM) rate of 2%, a 1-year NRM rate of 5%, a 2-year NRM rate of 7%, and a 5-year NRM rate of 13%. The 1-year, 2-year, and 5-year relapse rates were 30%, 34%, and 40%, respectively.

The 1-year overall survival (OS) rate was 65%, the 2-year OS rate was 58%, and the 5-year OS rate was 47%. Three cases of early mortality were noted, which were due to rapid progression, treatment-associated acute myeloid leukemia, or multi-organ failure/sepsis. Of the 43 late mortality cases, 31 were due to relapsed disease, 5 were due to infection, and 3 were due to organ failure.

The most common toxicity was infection, which was noted in 24 patients.

The researchers noted that patients who received ASCT between 2000 and 2010 were at a far greater risk of NRM than those who received ASCT between 2011 and 2016 (hazard ratio, 6.54), which may reflect general improvements in medical practices.

The authors concluded that “[a] revised [Hematopoietic Cell Transplantation-Comorbidity Index] for elderly patients, perhaps that de-emphasizes comorbidities such as solid tumors, which become increasingly common with age, may be useful in evaluation of these patients for ASCT candidacy.”

Reference

  1. Sun L, Li S, El‐Jawahri A, et al. Autologous stem cell transplantation in elderly lymphoma patients in their 70s: outcomes and analysis. Oncologist. 2017 Dec 28. doi: 10.1634/theoncologist.2017-0499 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs